Author: Jund, Rainer; Mondigler, Martin; Stammer, Holger; Stierna, Pontus; Bachert, Claus
Title: Herbal drug BNO 1016 is safe and effective in the treatment of acute viral rhinosinusitis Document date: 2015_1_2
ID: 3j8jcmzm_39
Snippet: Major symptom score (MSS). The baseline (mean MSS) at enrolment was without statistical differences between the two treatment groups (Table I) . MSS improved gradually in both groups during the 15-day treatment period by a mean of 10.02 ± 1.61 to 2.47 ± 2.55 for BNO 1016 and 9.87 ± 1.52 to 3.63 ± 3.63 with placebo (Table I, Figure 2 ). The difference between treatment groups at visit 5 was statistically significant in favor of the BNO 1016 pr.....
Document: Major symptom score (MSS). The baseline (mean MSS) at enrolment was without statistical differences between the two treatment groups (Table I) . MSS improved gradually in both groups during the 15-day treatment period by a mean of 10.02 ± 1.61 to 2.47 ± 2.55 for BNO 1016 and 9.87 ± 1.52 to 3.63 ± 3.63 with placebo (Table I, Figure 2 ). The difference between treatment groups at visit 5 was statistically significant in favor of the BNO 1016 product (FAS, p < 0.0001).
Search related documents:
Co phrase search for related documents- major symptom score and symptom score: 1, 2, 3
- major symptom score and treatment period: 1
- MSS major symptom score and symptom score: 1, 2, 3
- MSS major symptom score and treatment period: 1
- statistical difference and symptom score: 1, 2, 3
- statistical difference and treatment group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- statistical difference and treatment group difference: 1, 2, 3, 4, 5
- statistical difference and treatment period: 1, 2, 3, 4
- symptom score and treatment group: 1, 2, 3, 4, 5, 6, 7, 8, 9
- symptom score and treatment period: 1, 2, 3, 4, 5, 6
- table treatment group and treatment group: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date